Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
9.50
+0.08 (0.85%)
At close: Jan 17, 2025, 4:00 PM
9.52
+0.02 (0.21%)
After-hours: Jan 17, 2025, 7:14 PM EST
Intellia Therapeutics Employees
Intellia Therapeutics had 526 employees as of December 31, 2023. The number of employees decreased by 72 or -12.04% compared to the previous year.
Employees
526
Change (1Y)
-72
Growth (1Y)
-12.04%
Revenue / Employee
$81,913
Profits / Employee
-$992,935
Market Cap
967.56M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
NTLA News
- 16 hours ago - Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 3 days ago - Editas And Intellia: Strategic Shifts And Long-Term Investment Potential - Seeking Alpha
- 3 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Stockholders to Learn More About the Investigation - Accesswire
- 4 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Investors to Inquire about Securities Investigation - Accesswire
- 5 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Investors to Reach Out - Accesswire
- 6 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out - Accesswire
- 7 days ago - Intellia Therapeutics: Buying The Path To Commercialization - Seeking Alpha
- 7 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Connect - Accesswire